<DOC>
	<DOCNO>NCT00158977</DOCNO>
	<brief_summary>The RENEWAL 3 AVT device design treat patient suffer HF , history risk develop atrial ventricular arrhythmia</brief_summary>
	<brief_title>CONTAK RENEWAL 3 AVT</brief_title>
	<detailed_description>A clinical evaluation : - Confirm adverse interaction Ventricular Tachyarrhythmia ( ICD ) , Heart Failure ( HF ) Atrial Tachyarrhythmia ( AT ) therapy combine - Confirm Cardiac Resynchronization Therapy ( CRT ) Ventricular Tachyarrhythmia ( ICD ) therapy deliver presence atrial therapy - Demonstrate safety effectiveness atrial therapy heart failure population</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patients meet follow criterion give consideration inclusion clinical investigation : Meet device indication contraindication Willing capable providing informed consent , undergoing device implant , participate test associate clinical investigation approve clinical investigational center interval define protocol Prescribed stable optimal pharmacologic therapy heart failure Creatinine &lt; 2.5 mg/dL obtain two week prior enrollment Age 18 , legal age give inform consent specific state national law Geographically stable resident available followup Able provide document evidence one episodes AF/AT within 12 month implantation NOTE : Guidant recommend anticoagulation therapy per physician discretion . Patients exclude investigation meet one follow criterion : Have preexist nonGuidant leave ventricular lead Have preexist unipolar pacemaker explanted/abandoned Documented life expectancy less six month expect undergo heart transplant within next six month Have atrial tachyarrhythmia permanent ( i.e. , terminate spontaneously terminate medical intervention ) within 180 day prior enrollment Have know hypersensitivity 0.7 mg dose dexamethasone acetate Have surgically uncorrected primary valvular heart disease Currently require hemodialysis Have myocardial infarct , unstable angina , percutaneous coronary intervention , coronary artery bypass graft precede 30 day prior enrollment Have hypertrophic obstructive cardiomyopathy infiltrative cardiomyopathy ( e.g. , amyloidosis , sarcoidosis ) Have mechanical tricuspid heart valve Enrolled concurrent study , without Guidant write approval , may confound result study A Cerebral Vascular Event/ Transient Ischemic Attack within 12 month implantation During four week prior implantation , patient experience episode AF Â³ 48 hour duration anticoagulated adequate therapeutic level 4 week prior enrollment INR = 2.03.0 enrollment Women pregnant plan become pregnant Note : Women childbearing potential must negative pregnancy test within 7 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>heart failure</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>cardiac resynchronization therapy defibrillator</keyword>
</DOC>